Vanderbilt-Ingram Cancer Ctr — Nashville, Tennessee

Vanderbilt-Ingram Cancer Ctr is a clinical research site located in Nashville, Tennessee, United States 37232.

Crixeo Health Trust Score: 75/100 (FAIR). This profile has not yet been claimed by the site owner.

Vanderbilt-Ingram Cancer Ctr has participated in 13 clinical trials with 1 currently active.

Therapeutic areas: Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma.

Sponsors: Bristol-Myers Squibb, Hoffmann-La Roche, Merrimack Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 75/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Vanderbilt-Ingram Cancer Ctr?

Vanderbilt-Ingram Cancer Ctr has a Crixeo Trust Score of 75/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Vanderbilt-Ingram Cancer Ctr conducted?

Vanderbilt-Ingram Cancer Ctr has 13 clinical trials on record, with 1 currently active. Their work covers Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma.

Is Vanderbilt-Ingram Cancer Ctr accredited by Crixeo Health?

Yes — Vanderbilt-Ingram Cancer Ctr holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Vanderbilt-Ingram Cancer Ctr?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.